Bristol-Myers Squibb (BMY) is a major international pharmaceutical company that recently acquired Celgene in one of the largest pharmaceutical mergers in history. Following the merger, Bristol-Myers Squibb now has multiple blockbuster therapeutics, with the majority of the company’s revenue coming from their top three best selling therapeutics. Furthermore, Bristol-Myers Squibb currently boasts an impressive drug pipeline and is expected to market some of the top best selling therapeutics over the next few years. That being said, the company does come with challenges, including serious competition for their top selling therapeutics and their significant long-term debt.